AI is reshaping drug discovery, with Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci advancing computational platforms and pipelines.

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.

Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one has climbed nearly 400% in the past year alone.

In the past few days, Schrödinger, Inc. reported second-quarter 2026 results showing revenue of US$58.89 million and a shift to a US$5.98 million net profit, while also expanding its long-running collaboration with Bristol Myers Squibb to deploy its new agentic AI co-scientist, Bunsen, across that partner’s research organization. Alongside this earnings turnaround, Schrödinger’s AI agreement with Bristol Myers Squibb and the related ESOP shelf registration highlight both growing adoption of...

Schrodinger Inc (SDGR) reports robust Q2 2026 with record ACV growth, strategic AI advancements, and raised full-year drug discovery guidance despite margin pressures from hosted transition.

Schrodinger (NASDAQ:SDGR) said second-quarter annual contract value growth accelerated as demand broadened across large pharmaceutical customers, biotechnology companies and materials-science customers, while the company launched early access for Bunsen, its agentic AI co-scientist. Second-quarter

Schrodinger (SDGR) delivered earnings and revenue surprises of +113.33% and +15.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?